Abstracts tagged "Lupus nephritis"

Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 1798 • ACR Convergence 2024
CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis
Philip Carlucci¹, Nalani Sachan², Andrea Fava³, Brooke Cohen², Jasmine Shwetar⁴, Siddarth Gurajala⁵, Qian Xiao⁵, Joseph Mears⁶, Katie Preisinger², Devyn Zaminski⁷, Kristina Deonaraine⁸, Peter Izmirly⁹, Judith James¹⁰, Joel Guthridge¹⁰, Wade DeJager¹¹, David Wofsy¹², Cynthia Loomis², Gyles Ward², Ming Wu¹³, Chaim Putterman¹⁴, Deepak Rao¹⁵, Betty Diamond¹⁶, Derek Fine¹⁷, Jose Monroy-Trujillo¹⁷, H Michael Belmont⁷, William Apruzzese¹⁸, Anne Davidson¹⁹, Richard Furie²⁰, Paul Hoover²¹, Celine Berthier²², Maria Dall'Era²³, Diane Kamen²⁴, Kenneth Kalunian²⁵, Jennifer Anolik²⁶, Jennifer Barnas²⁷, Arnon Arazi²⁸, Soumya Raychaudhuri²⁹, Nir Hacohen³⁰, Robert Clancy³¹, Kelly Ruggles³², Michelle Petri³³ and Jill Buyon², and the Accelerating Medicines Partnership in RA/SLE, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴New York School of Medicine, Ann Arbor, MI, ⁵Harvard Medical School, Boston, MA, ⁶Michigan University, Ann Arbor, MI, ⁷NYU School of Medicine, New York, NY, ⁸Jacobs School of Medicine, University at Buffalo, Buffalo, NY, ⁹New York University Grossman School of Medicine, New York, NY, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, ¹²University of California San Francisco, SF, CA, ¹³Northwell, New York, NY, ¹⁴Albert Einstein College of Medicine, Safed, Israel, ¹⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁶The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁷Johns Hopkins School of Medicine, Baltimore, MD, ¹⁸Brigham and Women's Hospital, Everett, MA, ¹⁹Feinstein Institutes for Medical Research, Manhasset, NY, ²⁰Northwell Health, Manhasset, NY, ²¹Brigham and Women's Hospital, SWAMPSCOTT, MA, ²²University of Michigan, Ann Arbor, MI, ²³UCSF, Corte Madera, CA, ²⁴Medical University of South Carolina, Charleston, SC, ²⁵University of California San Diego, La Jolla, CA, ²⁶University of Rochester Medical Center, Rochester, NY, ²⁷University of Rochester, Rochester, NY, ²⁸Feinstein Institutes for Medical Research, Melrose, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰Broad Institute of MIT and Harvard, Boston, MA, ³¹Columbia University Medical Center, New York, NY, ³²NYU Grossman School of Medicine, Brooklyn, NY, ³³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Detection of urinary CXCL6, a member of the IL-8 chemokine family, has been linked to CKD and is a proposed marker of chronic damage…
Abstract Number: 2389 • ACR Convergence 2024
Choroidal Thickness in Active Lupus Nephritis
Leticia Maria Kolachinski R Brandao¹, Lucas Parente de Andrade², Débora Cordeiro do Rosário³, Paula Letícia De Queiroz e Barbosa⁴, Francisco Formiga³, Carolina Torres Ribeiro⁵, Tatiana do Nascimento Pedrosa³, Maria Fernanda Abalem de Sá Carricondo⁶, Pedro Carlos Carricondo², Eloisa Bonfa³ and Michelle Remiao Ugolini Lopes³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Campinas, SP, Brazil, ²Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, ⁵Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁶Ophthalmology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Lupus choroidopathy was reported to be a marker of severe systemic lupus erythematosus (SLE) activity, commonly associated with nephropathy. However, it remains controversial if…
Abstract Number: 0263 • ACR Convergence 2024
Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients
Eduardo Briones-García¹, Shaul Navarro-Lara², Marco A Ortiz-Bustamante², Iris Paola García Herrera³, Carla M Roman-Montes² and Guillermo A Guaracha-Basañez⁴, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ²Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán., México city, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a severe respiratory complication observed in certain rheumatic diseases, such as systemic lupus erythematosus (SLE), ANCA-associated vasculitides (AAV), and…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 1510 • ACR Convergence 2024
Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Nidia Meras⁸, Cintia Otaduy⁹, Elisa Novatti¹⁰, Valeria Arturi¹¹, Erika S. Palacios Santillan⁷, Boris Kisluk¹², Luciana González Lucero¹³, Eduardo Kerzberg¹⁴, Nicolás Pérez¹⁵, Cecilia Pisoni¹⁶, Paola Pirruccio¹⁷, María E. Crespo¹⁸, Ana Carolina Montandon¹⁹, Andrese A. Gasparin²⁰, Angela Duarte²¹, Laissa C. Alves Alvino²², Eloisa Bonfa²³, Emily Figuereido Neves²⁴, Lucas Victoria De Oliveira Martins²⁵, Iris Guerra²⁶, Milena Mimica Davet²⁷, Lizeth De La Hoz Rueda²⁸, Andrés Cadena Bonfanti²⁸, Roberth Rivera²⁹, Paola Coral Alvarado³⁰, John Fredy Jaramillo³¹, José Martínez³², Mario Moreno³³, Reyna E. Sánchez Briones³⁴, Mario Pérez Cristóbal³⁵, Eduardo Martin Nares³⁶, Yaneli Juárez-Vicuña³⁷, Yelitza González Bello³⁸, Octavio González³⁹, Leonardo R. Aguilar Rivera⁴⁰, Margarita Duarte⁴¹, Patricia Langjarth⁴², Wilkerson Pérez Medina⁴¹, Armando Calvo⁴³, Teresandris Polanco⁴⁴, Carina Pizzarossa⁴⁵, Gonzalo Silveira⁴⁶, Cristina Reategui⁴⁷, Graciela Alarcon⁴⁸, Urbano Sbarigia⁴⁹, Federico Zazzetti⁵⁰, Ashley Orillion⁵¹, Guillermo Pons-Estel⁵² and Bernardo Pons-Estel⁵², ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Córdoba, Córdoba, Spain, ⁹Hospital Córdoba, Cordoba, Spain, ¹⁰Hospital Privado Universitario de Córdoba, Córdoba, Spain, ¹¹Hospital HIGA San Martín, La Plata, Argentina, ¹²Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ¹³Hospital Padilla, Tucumán, Argentina, ¹⁴Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹⁵Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁶CEMIC, Buenos Aires, Argentina, ¹⁷Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, ¹⁸Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ²⁰Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²¹Universidad Federal de Pernambuco, Pernambuco, Brazil, ²²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁴Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ²⁸Universidad Simon Bolivar, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³⁷Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, CDMX, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, Mexico, ⁴⁰Servicio de Reumatología (CEAR). Hospital Universitario "Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico, ⁴¹Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Cayetano Heredia, San Martin de Porres, Peru, ⁴⁴Hospital Docente Padre Billini, Santo Domingo, Dominica, ⁴⁵Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁶Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁷Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁸The University of Alabama at Birmingham, Birmingham, AL, ⁴⁹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵⁰Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵¹Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: To evaluate health-related quality of life (HRQoL) in patients with active lupus nephritis (LN) at baseline and 12 months after treatment in relationship to…
Abstract Number: 1802 • ACR Convergence 2024
Heterogeneous Neutrophil Subsets Infiltrate Glomeruli of Lupus Nephritis Patients and Are Elevated in the Kidneys and Urine of Sunlight-induced Nephritis Flares
Noelle Kosarek¹, Joshua Skydel², Alecia Roy³, Fred Kolling¹, Lucas Salas¹, Christopher Burns⁴, Andrea Fava⁵ and Sladjana Skopelja-Gardner¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Divison of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Up to ~60% of SLE patients in North America will develop kidney disease, lupus nephritis (LN), one of the main contributors to disease morbidity…
Abstract Number: 2392 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Güllü Sandal Uzun¹ and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and idiopathic inflammatory myositis (IIM) are chronic, potentially severe autoimmune diseases, that may affect many organs/ systems. In this study, we…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 0660 • ACR Convergence 2024
Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis
Shivani Garg¹, Brad Rovin², Brad Astor¹, Tripti Singh¹, Lexie Kolton¹, Callie Saric¹, S. Sam Lim³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²The Ohio State University, Columbus, OH, ³Emory University, Atlanta, GA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
Abstract Number: 1511 • ACR Convergence 2024
Lupus Nephritis and Response to Treatment in Latin America
Rosana Quintana¹, Romina Nieto², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Marina Scolnik⁸, Carmen Funes Soaje⁹, Paula Alba¹⁰, Veronica Saurit¹¹, Mercedes Garcia¹², Guillermo Berbotto¹³, VERONICA BELLOMIO¹⁴, Wilfredo Patiño Grageda¹⁵, Graciela Gómez¹⁶, Cecilia Pisoni¹⁷, Ana Malvar¹⁸, Vicente Juarez¹⁹, Nilzio A. Da Silva²⁰, ODIRLEI MONTICIELO²¹, Henrique Ataide Mariz²², Francinne Machado Ribeiro²³, Eduardo Borba²⁴, Luciana Parente²⁴, Edgard Torres²⁵, Oscar Neira²⁶, Loreto Massardo²⁷, Gustavo Aroca Martínez²⁸, Carlos A. Cañas Davila²⁹, Gerardo Quintana López³⁰, Carlos Enrique Toro-Gutierrez³¹, Mario Moreno³², Andres Zuñiga³³, Miguel Angel Saavedra Salinas³⁴, Margarita Portela Hernandez³⁵, Hilda Fragoso-Loyo³⁶, Luis H. Silveira Torre³⁷, Ignacio García De La Torre³⁸, Carlos Abud Mendoza³⁹, Marcos Fonseca Hernández⁴⁰, Jorge Esquivel-Valerio⁴¹, Isabel Acosta Colman⁴², Jhonatan Losanto⁴³, Claudia Selene Mora Trujillo⁴⁴, Katiuzka Zuñiga Corrales⁴⁵, Roberto Muñoz Louis⁴⁶, Martin Rebella⁴⁷, Álvaro Danza⁴⁸ Manuel Ugarte-Gil⁴⁹, Graciela Alarcon⁵⁰, Urbano Sbarigia⁵¹, Federico Zazzetti⁵², Ashley Orillion⁵³, Guillermo Pons-Estel⁵⁴ and Bernardo Pons-Estel⁵⁴, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Hospital Italiano, Cordoba, Argentina, ¹⁰Hospital Cordoba, Cordoba, Spain, ¹¹hospital privado universitario de cordoba, Córdoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, ¹⁴Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁵Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Salta, Argentina, ²⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidad Federal de Pernambuco, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago de Chile, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³⁷Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ³⁸Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, ⁴¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital de Clínicas I, San Lorenzo, Paraguay, ⁴⁴Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴⁵Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ⁴⁶Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁷Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ⁴⁸Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ⁴⁹Universidad Cientifica del Sur, Lima, Lima, Peru, ⁵⁰The University of Alabama at Birmingham, Birmingham, AL, ⁵¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵²Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 1803 • ACR Convergence 2024
Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Magdalena Riedl Khursigara¹, Nicholas Gold², Thai-Son Tang³, JingJing Cao⁴, Daniela Dominguez⁴, Marisa Klein-Gitelman⁵, Dafna Gladman⁶, Daniel Goldman⁷, Elizabeth Harvey⁴, Mariko Ishimori⁸, Caroline Jefferies⁹, Diane Kamen¹⁰, Sylvia Kamphuis¹¹, Andrea Knight¹², Chia-Chi Lee¹³, Deborah Levy², Damien Noone⁴, Karen Onel¹⁴, Christine Peschken¹⁵, Michelle Petri⁷, Janet Pope¹⁶, Eleanor Pullenayegum⁴, Earl Silverman¹⁷, Zahi Touma¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Joan Wither²¹ and Linda Hiraki², and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), ¹University of Toronto, Cambridge, MA, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Erasmus University Medical Center, Rotterdam, Netherlands, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴HSS, New York, NY, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Silverman, Toronto, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹Self employed, Toronto, ON, Canada, ²⁰Cedars Sinai Medical Center, Studio City, CA, ²¹University Health Network, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS)…
Abstract Number: 2395 • ACR Convergence 2024
Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)
Antônio Silaide De Araújo-Júnior¹, Emília Sato², Alexandre Wagner Silva de Souza¹, Fábio Jennings¹, Gianna Mastroianni Kirsztajn³, Ricardo Sesso³ and Edgard Reis Neto⁴, ¹Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ³Division of Nephrology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, ⁴Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), and kidney biopsy is the gold…
Abstract Number: 0445 • ACR Convergence 2024
Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum
Liya Stolyar¹, Sadaf Sediqi², Richard Lafayette³, Maurice Druzin⁴, Saadiya Hawa⁵, Amanda Moyer⁶, Yashaar Chaichian² and Julia Simard², ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶Stanford University, San Bruno, CA
Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…
Abstract Number: 0661 • ACR Convergence 2024
Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, and AURORA, ¹Rush University Medical Center, Chicago, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Aurinia Pharmaceuticals, Dallas
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…

« Previous Page
1
…
3
4
5
6
7
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].